KRAS and non-small cell lung carcinoma: However, a recent clinical trial (NCT04735068) was disappointing in that the combination of binimetinib with HCQ in second- or later-line treatment of advanced KRAS-mutant NSCLC did not exhibit meaningful antitumor activity [250].